Angioedemas, Hereditary

Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study

6 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Functional, Gene Modification, Intellia, NTLA-2002, Phase 2 Clinical Trials, Swelling attacks

CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure

Intellia’s CRISPR Gene Editing Therapy Shows Promising Results in Reducing HAE Attacks

6 months ago talkbio0Tagged Angioedemas, Hereditary, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, gene therapy, Infrequent, Intellia

Intellia Therapeutics, CRISPR Gene Editing, Hereditary Angioedema (HAE), NTLA-2002, Clinical Trials, Gene Therapy, Rare Diseases

Poseida Therapeutics Advances Non-Viral Gene Editing Therapy for Hereditary Angioedema

6 months ago talkbio0Tagged Angioedemas, Hereditary, Cas-CLOVER, liver-directed gene therapy, non-viral gene, Poseida

Poseida Therapeutics, non-viral gene editing, hereditary angioedema (HAE), P-KLKB1-101, Cas-CLOVER, liver-directed gene therapy

Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy

11 months ago talkbio0Tagged Angioedemas, Hereditary, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, single-dose

Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials

Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy

11 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, NTLA-2002, single-dose

Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data

Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program

12 months ago talkbio0Tagged Angioedemas, Hereditary, Collaboration, Editas Medicine, KalVista, Myers, Partnership, preclinical program, squibb, T cell therapy

Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.